Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03682068 |
| Title | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | AstraZeneca |
| Indications |
ureter transitional cell carcinoma |
| Therapies |
Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | ESP | CAN | AUS |